Abstracts tagged "RANTES"

Abstract Number: 663 • 2016 ACR/ARHP Annual Meeting
Cytokine and Chemokine Levels in Serum and Tears As Disease Activity Biomarkers in Patients with Primary Sjögren´s Syndrome
Angel Alejandro Castillo-Ortiz¹, Rosa Elda Barbosa-Cobos², Lizbeth Becerril-Mendoza³, Gustavo Lugo-Zamudio⁴, Virgilio Lima-Gómez⁴, Adan Moreno-Eutimio⁵, Nayeli Nieto-Velázquez⁵ and Angel Tzec-Pérez⁵, ¹Rheumatology, Hospital Juárez de México, Mérida, Mexico, ²Rheumatology, Hospital Juárez de México, Mexico, Mexico, ³Hospital Juárez de México, Mexico, Mexico, ⁴Hospital Juárez de México, México city, Mexico, ⁵Hospital Juárez de México, Mexico city, Mexico
Background/Purpose: Evidence suggests that levels of different cytokines in primary Sjögren´s syndrome (pSS) are associated with cell infiltration degree within lacrimal and salivary glands and…
Abstract Number: 2153 • 2016 ACR/ARHP Annual Meeting
Syndecans Mediate Rantes/CCL5 Induced MMP-1 and MMP-13 Expression in Rheumatoid Arthritis Synovial Fibroblasts
Solomon Agere, Nahid Akhtar and Salahuddin Ahmed, Department of Pharmaceutical Sciences, Washington State University, College of Pharmacy, Spokane, WA
Background/Purpose: RANTES/CCL5 (RANTES) is a C-C chemokine that binds to its receptor (CCR5) and initiates inflammatory processes in rheumatoid arthritis (RA) by facilitating leukocyte…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].